InQpharm Group licenses technology from LiveLeaf for its animal health division

In a strategic move to strengthen its Animal Health portfolio with further unique natural antimicrobial technologies, InQpharm has acquired a license for one of the world’s most significant recent technologies in that field from LiveLeaf Inc to improve the health of production animals and horses. 

The license initially extends rights for all of Europe and much of Asia Pacific with InQpharm having an option on other significant territories. Branded LiveXtract™ in its native US market, this patented technology is based on two botanical compounds with a very well documented history of safe use. 

One of the main benefits of LiveXtract™ is that it improves the gastrointestinal health of young foodproducing animals and improves their growth at an expedient and safe rate. Academic studies and extensive experience from field trials have already demonstrated the highly significant benefit of this technology as a complimentary therapy to or in some applications even as a replacement of antibiotics. 

As of today, there have been 28 patents filed for LiveXtract™, with 18 broad patents already granted. 

InQpharm’s existing Vetrinol™, Vetrinol™ Plus and Vetrinol™ Neo product lines have already been successfully introduced in Europe for the prevention and treatment of reducing somatic cell count, sub-clinical mastitis and calf diarrhoea and this latest acquisition will give InQpharm critical mass as a leader in the field of bioactive based anti-microbials. The acquisition is fully in line with InQpharm’s vision of growing its natural healthcare solutions for the animal health industry. 

“We are excited to add this breakthrough nature-based technology to our already successful and highly diverse group of innovative offerings. This agreement is evidence of our continued commitment to seek out novel solutions to the challenges of sustainable food production,” said Thomas Hafner, founder and CEO of Zaluvida, InQpharm’s parent company. “These products are perfectly aligned with our focus on natural alternatives to antimicrobial overuse for growth promotion,” he added. 

Commenting on the deal, Alex Huang, founder and CEO of LiveLeaf said, "We are delighted to have found a powerful commercializations partner with global reach to deploy this important breakthrough. LiveXtract products provide production farmed animals with powerful immune benefits previously only available from a natural field diet. This agreement further validates the potential of our technology to help meet the world’s growing demand for protein without compromises to the future health of humanity.”